The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis
Primary Purpose
Intrauterine Adhesion
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
disposable balloon uterine stent
dried biological amnion graft
estradiol valerate tablets+dydrogesterone tablets
Sponsored by
About this trial
This is an interventional prevention trial for Intrauterine Adhesion focused on measuring Asherman syndrome, hysteroscopy, uterine stent, Estrogen, Amnion, Hysteroscopic Adhesiolysis
Eligibility Criteria
Inclusion Criteria:
- age 20-40 years;
- previously diagnostic hysteroscopy confirmed adhesion score >5, according to the American Fertility Society (AFS)classification of IUA;
- complains of menstruation disorder and reproductive dysfunction;
- informed consent.
Exclusion Criteria:
- premature menopause,
- presence of other intrauterine lesions (e.g. polyps, myoma, septa), and
- presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases),
- adhesions limited to the lower uterine cavity or the cervical canal.
Sites / Locations
- Beijing Obstetrics and Gynecology Hospital,Capital Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Uterine cavity barrier only
hormone
Arm Description
patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
Outcomes
Primary Outcome Measures
Incidence of adhesion information
Intrauterine adhesions under hysteroscopy
Secondary Outcome Measures
Menstruation Pattern
menstrual volume which was assessed by pictorial blood loss assessment chart
The change of AFS score
he American Fertility Society ( AFS ) scoring system (1988 version). Scores of 1-4, 5-8, and 9-12 were mild, moderate, and severe adhesions, respectively.
Full Information
NCT ID
NCT03351205
First Posted
November 20, 2017
Last Updated
November 20, 2017
Sponsor
Beijing Obstetrics and Gynecology Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03351205
Brief Title
The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis
Official Title
Randomized, Controlled Trial to Assess the Efficacy of Estrogen Therapy Combined With Disposable Balloon Uterine Stent and Dried Biological Amnion Graft in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 21, 2017 (Anticipated)
Primary Completion Date
November 21, 2018 (Anticipated)
Study Completion Date
November 22, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Obstetrics and Gynecology Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. The gold standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions. The recurrence of intrauterine adhesions is a major challenge in clinical practice. Intrauterine balloon has been used for the prevention of intrauterine adhesions. It has been reported that dried biological amnion graft was used to prevent adhesion after the operation of intrauterine adhesions. Estrogen is also used for postoperative prevention of intrauterine adhesions. Intrauterine balloon can reduce the recurrence of adhesions after operation. Disposable balloon uterine stent,which is an innovative intrauterine balloon,is specially designed to fit into the cavity of the uterus. Does Disposable balloon uterine stent and amniotic products combine estrogen therapy improve clinical outcomes? Therefore, this study was conducted.
Detailed Description
Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double (participant and outcomes Assessor) Primary Purpose: Prevention
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrauterine Adhesion
Keywords
Asherman syndrome, hysteroscopy, uterine stent, Estrogen, Amnion, Hysteroscopic Adhesiolysis
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Uterine cavity barrier only
Arm Type
Experimental
Arm Description
patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
Arm Title
hormone
Arm Type
Experimental
Arm Description
patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
Intervention Type
Device
Intervention Name(s)
disposable balloon uterine stent
Intervention Description
The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
Intervention Type
Procedure
Intervention Name(s)
dried biological amnion graft
Other Intervention Name(s)
amnion membrane
Intervention Description
Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.
Other Name: Human amnion membrane
Intervention Type
Drug
Intervention Name(s)
estradiol valerate tablets+dydrogesterone tablets
Other Intervention Name(s)
Progynova+dydrogesterone
Intervention Description
oral estradiol valerate tablets+dydrogesterone tablets
Primary Outcome Measure Information:
Title
Incidence of adhesion information
Description
Intrauterine adhesions under hysteroscopy
Time Frame
Within the first 3 months after surgery
Secondary Outcome Measure Information:
Title
Menstruation Pattern
Description
menstrual volume which was assessed by pictorial blood loss assessment chart
Time Frame
Within the first 3 months after surgery
Title
The change of AFS score
Description
he American Fertility Society ( AFS ) scoring system (1988 version). Scores of 1-4, 5-8, and 9-12 were mild, moderate, and severe adhesions, respectively.
Time Frame
Within the first 3 months after surgery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age 20-40 years;
previously diagnostic hysteroscopy confirmed adhesion score >5, according to the American Fertility Society (AFS)classification of IUA;
complains of menstruation disorder and reproductive dysfunction;
informed consent.
Exclusion Criteria:
premature menopause,
presence of other intrauterine lesions (e.g. polyps, myoma, septa), and
presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases),
adhesions limited to the lower uterine cavity or the cervical canal.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhu Ru, MD
Phone
13966636438
Email
zhuru19790202@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Wang Sha, MD
Phone
15201556908
Email
wangsha1020@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Duan Hua, MD
Organizational Affiliation
Beijing Obstetrics and Gynecology Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing Obstetrics and Gynecology Hospital,Capital Medical University
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liu Zhen
Phone
+8613718210767
Email
fcyykyb@163.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis
We'll reach out to this number within 24 hrs